Eficacia de los bifosfonatos en la espondilitis anquilosante

More documents

Recommendations

Info

ANEXO (estrategia de búsqueda para bifosfonatos) PubMed (("Diphosphonates"[Mesh] OR Bisphosphonates OR Organophosphorus Compounds OR Phosphonic Acids AND (hasabstract[text] AND (Humans[Mesh]) AND (English[lang] OR French[lang] OR Spanish[lang]) AND (Clinical Trial[ptyp] OR Meta‐Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Guideline[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Validation Studies[ptyp])))) AND (("Spondylitis, Ankylosing"[Mesh] OR Ankylosing Spondylitis Bechterew Disease OR Marie‐Struempell Disease OR Marie Struempell Disease OR Spondylarthritis Ankylopoietica OR Rheumatoid Spondylitis OR Spondylitis, Rheumatoid OR Bechterew's Disease OR Bechterews Disease OR Ankylosing Spondylitis pre radiological)) AND (hasabstract[text] AND (Humans[Mesh]) AND (English[lang] OR French[lang] OR Spanish[lang]) AND (Clinical Trial[ptyp] OR Meta‐Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR Comparative Study[ptyp] OR Guideline[ptyp] OR Journal Article[ptyp] OR Multicenter Study[ptyp] OR Validation Studies[ptyp])) Embase y Cochrane 1. Psoriatic Arthritis.mp. or Psoriatic Arthritis/ 2. (Psoriatic Arthritis or Psoriasis, Arthritic or Arthritic Psoriasis or Psoriasis Arthropathica or Arthritis or Psoriasis).af. 3. (Alibert Bazin Disease or Arthritis,Psoriasis or Arthritis, Psoriatic or Arthritis,Psoriatic or Arthritis Psoriatica or Arthropathic Psoriasis or Arthropathy,Psoriatic or Disease,Alibert Bazin or Polyarthritis,Psoriatic or Psoriasis,Arthritis or Psoriasis Arthropathica or Psoriasis Pustulosa or Arthropathica or Psoriatic Arthropathy or Psoriatic Polyarthritis or Psoriatic Rheumatism or Psoriatic or Rheumatoid Arthritis or Rheumatoid Arthritis,Psoriatic).af. 4. 3 or 2 or 1 5. Spondyloarthropathy/ 6. (Arthropathy, Spondylo or Spondylarthropathies or Spondylarthropathy).af. 7. (spondylarthropathy or spondylarthropathies undifferentiated or arthritis, psoriatic or arthritis, reactive or spondylitis, ankylosing or spondylarthropathies undifferentiated onset).af. 8. 5 or 6 or 7 9. Ankylosing Spondylitis/ 10. (Ankylosing Spondylitis or Bechterew Disease or Marie‐Struempell Disease or Marie Struempell Disease or Spondylarthritis Ankylopoietica or Rheumatoid Spondylitis or Spondylitis, Rheumatoid or Bechterew's Disease or Bechterews Disease or Ankylosing Spondylitis pre radiological).af. 11. (Ankylating Spondylitis or Ankylopoietic Spondylarthritis or Ankylopoietic Spondylitis or Ankylosing Spine or Ankylosing Spondilitis or Ankylosing Spondylarthritis or Ankylosing Spondylarthrosis or Ankylosis Spondylitis or Ankylotic Spondylitis or Bechterew Disease or Bekhterev Disease or Morbus BechterewOR Spinal Ankylosis or Spine Ankylosis or Spondylarthritis Ankylopoietica or Spondylarthritis Ankylosans or Spondylarthrosis
Ankylopoietica or Spondylitis Ankylopoetica or Spondylitis Ankylopoietica or Spondylitis, Ankylosing or Spondyloarthritis Ankylopoietica or Vertebral Ankylosis).af. 12. 9 or 11 or 10 13. (Comparative Study or Controlled study or Clinical study or Case Control Study or Clinical trial or Controlled Clinical Trial or Randomized Controlled Trial or Meta‐Analysis or Practice Guideline or Comparative Study or Controlled Clinical Trial or Multicenter Study).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] 14. DRUG EFFICACY.mp. or Drug Efficacy/ 15. (Drug Effectiveness or Drug Effectivity or Drug Efficiency).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] 16. Treatment Outcome.mp. or Treatment Outcome/ 17. Treatment Outcome.mp. or Treatment Outcome/ 18. (((Outcome Treatment or Rehabilitation Outcome or Outcome Rehabilitation or Treatment Effectiveness or Effectiveness Treatment or Treatment Efficacy or Efficacy Treatment or Medical Futility or Outcome) and Process Assessment) or Outcome Management or Therapy Outcome).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] 19. 15 or 18 or 16 or 14 or 17 20. (Comparative Study or Controlled study or Clinical study or Case Control Study or Clinical trial or Controlled Clinical Trial or Randomized Controlled Trial or Meta‐Analysis or Practice Guideline or Comparative Study or Controlled Clinical Trial or Multicenter Study).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] 21. Thalidomide/ 22. (Thalomid or Celgene Brand of Thalidomide or Sedoval).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name] 23. (Thalomid or Celgene Brand of Thalidomide or Sedoval).af. 24. 22 or 21 or 23 25. Diphosphonates.mp. or Bisphosphonic Acid Derivative/ 26. Bisphosphonates OR Organophosphorus Compounds OR Phosphonic Acids 27. Biphosphonate OR Biphosphonates OR Bisphosphonate OR Bisphosphonate OR Derivative OR Bisphosphonates OR Diphosphonate Derivative OR Diphosphonates OR Diphosphonate Series OR Diphosphonic Acid Derivative OR Bisphosphonates OR Organophosphorus Compounds OR Phosphonic Acids 28. 27 or 25 or 26 29. Interleukin 1 Receptor Antagonist Protein.mp. or Interleukin 1 Receptor Blocking Agent/ 30. Interleukin 1 Receptor Antagonist Protein.af. 31. (Urine‐Derived IL1 Inhibitor or IL1 Inhibitor, Urine‐Derived or Urine Derived IL1 Inhibitor or IL1 Febrile Inhibitor or Febrile Inhibitor IL1 or Interleukin 1 Inhibitor Urine or IL‐1 Inhibitor
Page 1 and 2: Eficacia de los bifosfonatos en la
Page 3 and 4: Systematic literature search of the
Page 5: Conclusiones: Los bifosfonatos podr
Page 9 and 10: 55. 54 and 20 56. limit 55 to (huma

Eficacia de los bifosfonatos en la espondilitis anquilosante

Create successful ePaper yourself

Delete template?

Save as template?